ANAPTYSBIO, INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01 Regulation FD.

On November 15, 2021, AnaptysBio issued a press release announcing rosnilimab healthy volunteer phase 1 top-line data. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

The information within this report, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this report and in the accompanying exhibits shall not be incorporated by reference into any registration statement or other document filed by AnaptysBio with the Securities and Exchange Commission, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in such filing (or any reference to this Current Report on Form 8-K generally), except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit Number               Exhibit Title or Description
  99.1                       Press release issued by AnaptysBio, Inc. regarding rosnilimab healthy
                             volunteer phase 1 top-line data, dated November 15, 2021
104                          Cover Page Interactive Data File (the cover page XBRL tags are
                             embedded within the inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses